Jeffrey Tyner attended Grinnell College and Washington University in St. Louis and is currently a Professor at the Knight Cancer Institute, Oregon Health & Science University. Jeff’s research is focused towards drug combinations to enhance therapeutic efficacy and circumvent drug resistance. Jeff has developed a functional genomics approach applied to primary cells from hematologic malignancy patients. This approach employs high-throughput drug and genome-wide CRISPR screening of primary leukemia patient samples and model cell lines. Combining these data genomics facilitates discovery of prioritized drug combinations and therapeutic approaches for acute myeloid leukemia.
« Go Back